Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 10/20 | 0.67 |
| ▸ | ESR1 | P03372 | 6/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | PGR | P06401 | 2/20 | 0.67 |
| ▸ | AR | P10275 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.67 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.67 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11788270 | 1.00 | STS (0.67) | STSESR1LMNAKMT2AMAPT | |
| SCHEMBL11780732 | 1.00 | STS (0.67) | STSESR1LMNAKMT2AMAPT | |
| SCHEMBL11783196 | 0.99 | STS (0.69) | STSESR1LMNAKMT2AMAPT | |
| SCHEMBL5158101 | 0.96 | ESR1 (0.70) | STSESR1LMNAKMT2AMAPT | |
| SCHEMBL5157957 | 0.91 | ESR1 (0.69) | STSESR1LMNAKMT2AMAPT | |
| SCHEMBL11239527 | 0.87 | LMNA (0.66) | STSESR1LMNAKMT2AMAPT | |
| SCHEMBL13345142 | 0.87 | ESR1 (0.72) | STSESR1LMNAKMT2AMAPT | |
| SCHEMBL14395341 | 0.87 | ESR1 (0.72) | STSESR1LMNAKMT2AMAPT | |
| SCHEMBL5158676 | 0.87 | ESR1 (0.72) | STSESR1LMNAKMT2AMAPT | |
| SCHEMBL7191265 | 0.84 | LMNA (0.72) | STSESR1LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229811-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GRI BIO INC (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | STS 383/4885ESR1 1835/4885LMNA 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.